Payment overview · 2025
General Payments
$349.54
10 reported records · 5 companies
Healthcare provider profile · identity verified
Amit Sagar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROMULUS, MI · NPI 1760427652
Verified facts
What the public records show
CMS Open Payments records show Amit Sagar, M.D. received $349.54 in general payments during 2025 across 10 reported records.
Kerecis Limited accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $167.57 | 47.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.42 | 21.3% | 4 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $44.06 | 12.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.52 | 11.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.97 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.54 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $167.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $167.57 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $44.06 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $44.06 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 190 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
37 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
190 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 459 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 125 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 89 |
| Gabapentin | Gabapentin | 193 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 190 | 38 |
| Lisinopril | Lisinopril | 184 | 56 |
| Metformin Hcl | Metformin Hcl | 168 | 47 |
| Ibuprofen | Ibuprofen | 151 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 34 |
| Omeprazole | Omeprazole | 103 | 31 |
| Furosemide | Furosemide | 98 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 35 |
| Ozempic | Semaglutide | 93 | 13 |
| Naproxen | Naproxen | 88 | 36 |
| Losartan Potassium | Losartan Potassium | 86 | 30 |
| Alprazolam | Alprazolam | 78 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | 18 |
| Chlorthalidone | Chlorthalidone | 69 | 25 |
| Carvedilol | Carvedilol | 66 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 20 |
| Glipizide Er | Glipizide | 59 | 16 |
| Topiramate | Topiramate | 59 | 18 |
| Ondansetron Odt | Ondansetron | 54 | 26 |
| Trazodone Hcl | Trazodone Hcl | 54 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 49 | 47 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 19 |
| Sertraline Hcl | Sertraline Hcl | 45 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 41 | 14 |
| Tramadol Hcl | Tramadol Hcl | 41 | 17 |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Famotidine | Famotidine | 39 | 17 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Eliquis | Apixaban | 38 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 27 |
| Simvastatin | Simvastatin | 37 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Prednisone | Prednisone | 36 | 26 |
| Meclizine Hcl | Meclizine Hcl | 35 | 13 |
| Glipizide | Glipizide | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 12 |
| Meloxicam | Meloxicam | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | 11 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | 11 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.54 · 10 records | Kerecis Limited | AREXVY, Flexitouch Plus, Kerecis GraftGuide, Kerecis SurgiClose, NUZYRA, Nimbl, Ozempic, SHINGRIX, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error